Amgen Astellas BioPharma is Drug Discovery in Japan that focus on Acute Lymphoblastic Leukemia business. Founded in 2013. They cover business area such as manufacturer, pharmaceutical product, Evolocumab, Romosozumab, Blinatumomab, Hypercholesterolemia, Osteoporosis, Acute Lymphoblastic Leukemia.
2013
( 11 years old in 2024 )
Acute Lymphoblastic Leukemia
-
Sapia Tower, 1-7-12 Marunouchi
Chiyoda-ku
Tokyo, 100-0005
Japan
Private
manufacturerpharmaceutical productEvolocumabRomosozumabBlinatumomabHypercholesterolemiaOsteoporosisAcute Lymphoblastic Leukemia
* We use standard office opening hours in near Amgen Astellas BioPharma's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Amgen Astellas BioPharma is Drug Discovery business from Japan that founded in 2013 (11 years old in 2024), Amgen Astellas BioPharma business is focusing on Acute Lymphoblastic Leukemia.
Amgen Astellas BioPharma headquarter office and corporate office address is located in Sapia Tower, 1-7-12 Marunouchi Chiyoda-ku Tokyo, 100-0005 Japan.
Amgen Astellas BioPharma was founded in Japan.
In 2024, Amgen Astellas BioPharma is currently focus on Acute Lymphoblastic Leukemia sector.
Above is snippet of Google Trends for "Acute Lymphoblastic Leukemia" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Amgen Astellas BioPharma, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
